Targeting IL-4 for the Treatment of Atopic Dermatitis
Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual i...
Gespeichert in:
| Veröffentlicht in: | ImmunoTargets and therapy Jg. 9; S. 151 - 156 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Macclesfield
Dove Medical Press Limited
01.01.2020
Taylor & Francis Ltd Dove Dove Medical Press |
| Schlagworte: | |
| ISSN: | 2253-1556, 2253-1556 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4. Keywords: atopic dermatitis, IL-4, IL-4 inhibitor, dupilumab, pascolizumab, pitrakinra |
|---|---|
| Bibliographie: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ISSN: | 2253-1556 2253-1556 |
| DOI: | 10.2147/ITT.S260370 |